|
시장보고서
상품코드
1794614
세계의 말초신경병증 치료 시장Peripheral Neuropathy Treatment |
||||||
Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
말초신경병증 치료 세계 시장은 2030년까지 22억 달러에 달할 전망
2024년에 19억 달러로 추정되는 말초신경병증 치료 세계 시장은 분석 기간인 2024-2030년에 CAGR 2.8%로 성장하여 2030년에는 22억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 약물요법은 CAGR 2.2%를 기록하며 분석 기간 종료시에는 13억 달러에 달할 것으로 예측됩니다. 비약물요법 분야의 성장률은 분석 기간 동안 CAGR 3.9%로 추정됩니다.
미국 시장은 5억 1,850만 달러로 추정, 중국은 CAGR 5.2%로 성장 예측
미국의 말초신경병증 치료 시장은 2024년에는 5억 1,850만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 5.2%로 2030년까지 4억 3,410만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.1%와 2.1%로 예측됩니다. 유럽에서는 독일이 CAGR 1.6%로 성장할 것으로 예측됩니다.
세계의 말초신경병증 치료 시장 - 주요 동향과 촉진요인 정리
말초신경병증 치료가 의료 시스템 전반에서 임상적 우선순위가 높아지는 이유는 무엇일까?
말초신경병증은 말초신경의 손상으로 인해 발생하는 복잡하고 종종 진행성 병증으로 통증, 무감각, 마비, 무감각, 근력저하 등의 증상을 유발합니다. 원인으로는 당뇨병, 화학요법, 자가면역질환, 감염, 비타민 결핍 등을 들 수 있습니다. 전 세계적으로 당뇨병과 만성질환의 유병률이 증가하는 가운데, 말초신경병증은 신경학 및 통증 관리에서 중요한 관심사로 떠오르고 있습니다.
치료 접근법은 일반적으로 대증요법이며, 통증 완화, 기능 회복, 질병 진행 억제에 중점을 두고 있습니다. 만병통치약이 존재하지 않는 이상, 임상적 초점은 여전히 다제 병용요법의 최적화에 맞춰져 있습니다. 여기에는 약리학적 관리, 신체적 재활, 생활습관 개선, 기저질환에 대한 표적 중재 등이 포함됩니다.
약리학적 치료와 비약리학적 치료는 어떻게 진화하고 있는가?
약리학적 치료에는 프레가발린, 가바펜틴 등의 항경련제, 듀록세틴 등의 항우울제, 캡사이신 패치, 리도카인 등의 외용제 등이 있습니다. 이들은 신경병증성 통증의 관리를 목적으로 하지만, 반응은 개인차가 있는 경우가 많습니다. 특히 당뇨병성 신경장애나 화학요법으로 인한 신경장애의 경우, 신경기능을 재생시키거나 퇴행에 제동을 걸 수 있는 질환 교정 치료법을 찾아내기 위한 노력이 계속되고 있습니다.
물리치료, 경피적 전기신경자극(TENS), 침술과 같은 비약리학적 접근법은 만성 통증 조절 및 감각 개선에 도움을 줄 수 있는 방법으로 각광받고 있습니다. 대사성 신경장애의 경우, 특히 α-리포산과 비타민 B12를 함유한 영양보충제가 사용됩니다. 장기적인 장애를 관리하고 삶의 질을 향상시키기 위해 약물 치료와 지지요법을 결합한 환자 맞춤형 치료 경로가 점점 더 많아지고 있습니다.
치료 수요는 어디에서 증가하고, 어떤 계층이 가장 큰 영향을 받는가?
치료 수요가 가장 높은 계층은 당뇨병 환자, 암 생존자, 노인층입니다. 당뇨병성 신경병증은 여전히 주요 아형이며, 고소득 국가와 중산층 국가 모두에서 유병률이 증가하고 있습니다. 종양 클리닉에서 화학요법 유발성 말초신경병증(CIPN)의 사례가 증가하고 있으며, 이는 환자의 회복과 삶의 질에 영향을 미치는 용량 제한적 부작용입니다.
일차의료와 신경과에서는 조기발견과 통합치료에 대한 수요가 증가하고 있습니다. 농촌 지역이나 진단이 미흡한 지역에서는 진단이 늦어지고 증상이 관리되지 않을 위험이 남아있습니다. 종합적인 치료 서비스를 제공하는 데 있어 병원, 전문 통증 클리닉, 재택의료 서비스 제공자가 중요한 역할을 담당하고 있습니다. 공중보건 캠페인과 의료진에 대한 교육 활동도 조기 발견 및 조기 의뢰에 기여하고 있습니다.
말초신경병증 치료 시장의 성장은 몇 가지 요인에 의해 주도됩니다...
말초신경병증 치료 시장의 성장은 당뇨병 및 암과 관련된 신경병증의 유병률 증가, 만성 통증 관리에 대한 관심 증가, 약리요법의 광범위한 가용성 등의 요인에 의해 주도될 것으로 예상됩니다. 국소 제제의 발전, 신경병증성 통증 치료제의 내약성 향상, 개별화된 치료 계획이 임상적 성과를 높이고 있습니다.
비오피오이드성 통증 치료제 및 새로운 신경 보호 화합물의 개발로 치료 옵션이 확대되고 있습니다. 환자와 임상의들 사이에서 인식이 높아지고 증상 모니터링과 원격 통증 관리를 위한 디지털 도구가 통합되면서 장기적인 치료 모델을 지지하고 있습니다. 헬스케어 시스템이 만성질환 관리 인프라에 투자하는 가운데, 효과적인 복합 신경병증 치료에 대한 수요는 전 세계적으로 계속 증가하고 있습니다.
부문
치료법(약물요법, 비약물요법), 유형(당뇨병성 말초신경병증, 화학요법 유발성 말초신경병증, 기타 유형)
조사 대상 기업 사례
- Acorda Therapeutics
- Arbor Pharmaceuticals
- Biogen Inc.
- Biohaven Pharmaceuticals
- Boehringer Ingelheim
- Cipla Limited
- Daiichi Sankyo
- Eli Lilly and Company
- GlaxoSmithKline(GSK)
- Grunenthal GmbH
- Johnson & Johnson
- Lupin Limited
- MediciNova Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Regenacy Pharmaceuticals
- Sorrento Therapeutics
- Teva Pharmaceutical Industries
- Vertex Pharmaceuticals
AI 통합
우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.
Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.
목차
제1장 조사 방법
제2장 주요 요약
- 시장 개요
- 주요 기업
- 시장 동향과 촉진요인
- 세계 시장 전망
제3장 시장 분석
- 미국
- 캐나다
- 일본
- 중국
- 유럽
- 프랑스
- 독일
- 이탈리아
- 영국
- 스페인
- 러시아
- 기타 유럽
- 아시아태평양
- 호주
- 인도
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 아르헨티나
- 브라질
- 멕시코
- 기타 라틴아메리카
- 중동
- 이란
- 이스라엘
- 사우디아라비아
- 아랍에미리트
- 기타 중동
- 아프리카
제4장 경쟁
KSM 25.08.28Global Peripheral Neuropathy Treatment Market to Reach US$2.2 Billion by 2030
The global market for Peripheral Neuropathy Treatment estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2024-2030. Pharmacological Therapy, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Non-Pharmacological Therapy segment is estimated at 3.9% CAGR over the analysis period.
The U.S. Market is Estimated at US$518.5 Million While China is Forecast to Grow at 5.2% CAGR
The Peripheral Neuropathy Treatment market in the U.S. is estimated at US$518.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$434.1 Million by the year 2030 trailing a CAGR of 5.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.
Global Peripheral Neuropathy Treatment Market - Key Trends & Drivers Summarized
Why Is Peripheral Neuropathy Treatment Gaining Clinical Priority Across Health Systems?
Peripheral neuropathy is a complex, often progressive condition resulting from damage to peripheral nerves, leading to symptoms such as pain, numbness, tingling, and muscle weakness. Causes include diabetes, chemotherapy, autoimmune disorders, infections, and vitamin deficiencies. As the incidence of diabetes and chronic diseases rises globally, peripheral neuropathy is emerging as a significant concern in neurology and pain management.
Treatment approaches are typically symptomatic, focusing on pain relief, functional restoration, and slowing disease progression. Given the absence of a universal cure, the clinical focus remains on optimizing multimodal therapies. This includes pharmacological management, physical rehabilitation, lifestyle modification, and targeted interventions for underlying conditions.
How Are Pharmacological and Non-Pharmacological Therapies Evolving?
Pharmacological treatment includes anticonvulsants such as pregabalin and gabapentin, antidepressants like duloxetine, and topical agents including capsaicin patches and lidocaine. These aim to manage neuropathic pain, although individual response often varies. Efforts are ongoing to identify disease-modifying treatments that can regenerate nerve function or halt degeneration, particularly in diabetic and chemotherapy-induced neuropathy.
Non-pharmacological approaches such as physical therapy, transcutaneous electrical nerve stimulation (TENS), and acupuncture are gaining traction for chronic pain control and sensory improvement. Nutritional supplements, especially those containing alpha-lipoic acid and vitamin B12, are used in metabolic neuropathies. Patient-tailored care pathways are increasingly combining pharmacologic and supportive therapies to manage long-term disability and improve quality of life.
Where Is Treatment Demand Rising and Which Demographics Are Most Affected?
The highest treatment demand is among individuals with diabetes, cancer survivors, and elderly populations. Diabetic neuropathy remains the leading subtype, with growing prevalence in both high- and middle-income countries. Oncology clinics are seeing increased cases of chemotherapy-induced peripheral neuropathy (CIPN), a dose-limiting side effect impacting patient recovery and quality of life.
In primary care and neurology practices, demand for early detection and integrated treatment is growing. Rural and underdiagnosed populations remain at risk of late-stage diagnosis and unmanaged symptoms. Hospitals, specialty pain clinics, and home care providers are key players in delivering comprehensive treatment services. Public health campaigns and provider education initiatives are also contributing to earlier recognition and referral.
Growth in the Peripheral Neuropathy Treatment market is driven by several factors…
Growth in the peripheral neuropathy treatment market is driven by factors such as rising prevalence of diabetes and cancer-related neuropathy, increasing focus on chronic pain management, and wider availability of pharmacologic therapies. Advances in topical formulations, improved tolerability of neuropathic pain drugs, and personalized treatment plans are enhancing clinical outcomes.
Development of non-opioid pain therapies and novel neuroprotective compounds is expanding therapeutic options. Greater awareness among patients and clinicians, along with integration of digital tools for symptom monitoring and remote pain management, is supporting long-term care models. As healthcare systems invest in chronic disease management infrastructure, demand for effective, multimodal neuropathy treatment continues to expand globally.
SCOPE OF STUDY:
The report analyzes the Peripheral Neuropathy Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Therapy (Pharmacological Therapy, Non-Pharmacological Therapy); Type (Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy, Other Types)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 39 Featured) -
- Acorda Therapeutics
- Arbor Pharmaceuticals
- Biogen Inc.
- Biohaven Pharmaceuticals
- Boehringer Ingelheim
- Cipla Limited
- Daiichi Sankyo
- Eli Lilly and Company
- GlaxoSmithKline (GSK)
- Grunenthal GmbH
- Johnson & Johnson
- Lupin Limited
- MediciNova Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Regenacy Pharmaceuticals
- Sorrento Therapeutics
- Teva Pharmaceutical Industries
- Vertex Pharmaceuticals
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tariff Impact on Global Supply Chain Patterns
- Peripheral Neuropathy Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Diabetic Population and Chemotherapy-Induced Neuropathy Cases Spur Demand for Peripheral Neuropathy Treatment
- Growth in Awareness and Early Screening Initiatives Throws the Spotlight on Timely Multimodal Interventions
- OEM Innovation in Neuromodulation Devices and Wearable Stimulators Enhances Non-Pharmacological Management Options
- Expansion of Topical and Oral Drug Formulations Strengthens Accessibility for Diverse Patient Profiles
- Increased Research on Nerve Regeneration and Neuroprotective Agents Fuels Development of Disease-Modifying Therapies
- Surge in Aging Population With Chronic Pain and Comorbidities Expands the Need for Safe, Long-Term Management Strategies
- OEM Focus on Drug Delivery Systems Targeting Peripheral Nerve Pathways Enhances Pain Relief Efficacy
- Adoption of Cognitive Behavioral Therapy and Tele-Rehabilitation Expands Holistic Management Approach
- Rising Demand for Personalized Medicine Supports Pharmacogenomic Profiling for Tailored Treatment
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Peripheral Neuropathy Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Peripheral Neuropathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 4: World 16-Year Perspective for Peripheral Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Pharmacological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Pharmacological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 7: World 16-Year Perspective for Pharmacological Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Non-Pharmacological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Non-Pharmacological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 10: World 16-Year Perspective for Non-Pharmacological Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Diabetic Peripheral Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Diabetic Peripheral Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 13: World 16-Year Perspective for Diabetic Peripheral Neuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 16: World 16-Year Perspective for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 19: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 20: USA Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 21: USA Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 22: USA 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 23: USA Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 24: USA Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 25: USA 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- CANADA
- TABLE 26: Canada Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 27: Canada Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 28: Canada 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 29: Canada Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 30: Canada Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 31: Canada 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- JAPAN
- Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 32: Japan Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 33: Japan Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 34: Japan 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 35: Japan Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 36: Japan Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 37: Japan 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- CHINA
- Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 38: China Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 39: China Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 40: China 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 41: China Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 42: China Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 43: China 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- EUROPE
- Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 44: Europe Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 45: Europe Historic Review for Peripheral Neuropathy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 46: Europe 16-Year Perspective for Peripheral Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
- TABLE 47: Europe Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 48: Europe Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 49: Europe 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 50: Europe Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 51: Europe Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 52: Europe 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- FRANCE
- Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 53: France Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 54: France Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 55: France 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 56: France Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 57: France Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 58: France 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- GERMANY
- Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 59: Germany Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 60: Germany Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 61: Germany 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 62: Germany Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 63: Germany Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 64: Germany 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- ITALY
- TABLE 65: Italy Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 66: Italy Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 67: Italy 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 68: Italy Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 69: Italy Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 70: Italy 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- UNITED KINGDOM
- Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 71: UK Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 72: UK Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 73: UK 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 74: UK Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 75: UK Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 76: UK 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- SPAIN
- TABLE 77: Spain Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 78: Spain Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 79: Spain 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 80: Spain Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 81: Spain Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 82: Spain 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- RUSSIA
- TABLE 83: Russia Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 84: Russia Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 85: Russia 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 86: Russia Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 87: Russia Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 88: Russia 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- REST OF EUROPE
- TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 90: Rest of Europe Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 91: Rest of Europe 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 93: Rest of Europe Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 94: Rest of Europe 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- ASIA-PACIFIC
- Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 96: Asia-Pacific Historic Review for Peripheral Neuropathy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 97: Asia-Pacific 16-Year Perspective for Peripheral Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
- TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 99: Asia-Pacific Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 100: Asia-Pacific 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 102: Asia-Pacific Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 103: Asia-Pacific 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- AUSTRALIA
- Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 104: Australia Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 105: Australia Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 106: Australia 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 107: Australia Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 108: Australia Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 109: Australia 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- INDIA
- Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 110: India Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 111: India Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 112: India 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 113: India Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 114: India Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 115: India 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- SOUTH KOREA
- TABLE 116: South Korea Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 117: South Korea Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 118: South Korea 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 119: South Korea Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 120: South Korea Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 121: South Korea 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 123: Rest of Asia-Pacific Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 126: Rest of Asia-Pacific Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- LATIN AMERICA
- Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 128: Latin America Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 129: Latin America Historic Review for Peripheral Neuropathy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 130: Latin America 16-Year Perspective for Peripheral Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
- TABLE 131: Latin America Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 132: Latin America Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 133: Latin America 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 134: Latin America Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 135: Latin America Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 136: Latin America 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- ARGENTINA
- TABLE 137: Argentina Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 138: Argentina Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 139: Argentina 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 140: Argentina Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 141: Argentina Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 142: Argentina 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- BRAZIL
- TABLE 143: Brazil Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 144: Brazil Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 145: Brazil 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 146: Brazil Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 147: Brazil Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 148: Brazil 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- MEXICO
- TABLE 149: Mexico Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 150: Mexico Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 151: Mexico 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 152: Mexico Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 153: Mexico Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 154: Mexico 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 156: Rest of Latin America Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 157: Rest of Latin America 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 159: Rest of Latin America Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 160: Rest of Latin America 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- MIDDLE EAST
- Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 161: Middle East Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 162: Middle East Historic Review for Peripheral Neuropathy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 163: Middle East 16-Year Perspective for Peripheral Neuropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
- TABLE 164: Middle East Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 165: Middle East Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 166: Middle East 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 167: Middle East Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 168: Middle East Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 169: Middle East 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- IRAN
- TABLE 170: Iran Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 171: Iran Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 172: Iran 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 173: Iran Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 174: Iran Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 175: Iran 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- ISRAEL
- TABLE 176: Israel Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 177: Israel Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 178: Israel 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 179: Israel Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 180: Israel Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 181: Israel 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- SAUDI ARABIA
- TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 183: Saudi Arabia Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 184: Saudi Arabia 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 186: Saudi Arabia Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 187: Saudi Arabia 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 188: UAE Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 189: UAE Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 190: UAE 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 191: UAE Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 192: UAE Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 193: UAE 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 195: Rest of Middle East Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 196: Rest of Middle East 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 198: Rest of Middle East Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 199: Rest of Middle East 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
- AFRICA
- Peripheral Neuropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 200: Africa Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 201: Africa Historic Review for Peripheral Neuropathy Treatment by Therapy - Pharmacological Therapy and Non-Pharmacological Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 202: Africa 16-Year Perspective for Peripheral Neuropathy Treatment by Therapy - Percentage Breakdown of Value Sales for Pharmacological Therapy and Non-Pharmacological Therapy for the Years 2014, 2025 & 2030
- TABLE 203: Africa Recent Past, Current & Future Analysis for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 204: Africa Historic Review for Peripheral Neuropathy Treatment by Type - Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
- TABLE 205: Africa 16-Year Perspective for Peripheral Neuropathy Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy and Other Types for the Years 2014, 2025 & 2030
IV. COMPETITION
샘플 요청 목록